SNYRQNasdaqMedicinal Chemicals & Botanical ProductsUS GAAP · USD

Synergy CHC Corp.

Synergy CHC Corp. is a U.S.-based consumer health company built around branded nutraceutical and ready-to-drink products. Its portfolio includes FOCUSfactor, a brain-health supplement line, and Flat Tummy, a lifestyle brand focused on weight-management and related nutritional products.

Liikevaihto30,4milj. USD
−12,8 %v/v
Liikevoitto (EBIT)−8,5milj. USD
−245,8 %v/v
EBIT-marginaali−27,8%
−44,5 %-yks.v/v
Nettotulos−12,3milj. USD
−680,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2017–2025

−200204060milj. USD2017: 36 milj. USD2017: EBIT 1,8 milj. USD20172018: 34 milj. USD2018: EBIT −4,9 milj. USD20182019: 29 milj. USD2019: EBIT −8,0 milj. USD20192023: 43 milj. USD2023: EBIT 11 milj. USD20232024: 35 milj. USD2024: EBIT 5,8 milj. USD20242025: 30 milj. USD2025: EBIT −8,5 milj. USD202530−8,5
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Nutraceuticals88 %

Dietary supplements and related consumer health products sold under the company's brands.

Ready-to-Drink Beverages8 %

Packaged beverage extensions tied to the FOCUSfactor brand.

License Revenue4 %

Royalties or license fees from agreements to expand brands into selected territories.

Tuotteet

Raportoitu · osuus liikevaihdosta
73,2%26,8%FY2025100 %
  • Retail73,2 %
  • Online26,8 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

The company sells to consumers seeking brain-health, wellness, and weight-management products, primarily through branded retail and distribution channels. It also monetizes brand assets through licensing arrangements in selected foreign territories, which broadens reach without requiring direct local retail operations.

Consumer supplement buyers

Buy FOCUSfactor products for brain-health and general wellness use.

Weight-management consumers

Buy Flat Tummy products for lifestyle and nutritional support.

Ready-to-drink beverage consumers

Buy FOCUSfactor RTDs as a convenient extension of the brand.

Retail and distribution partners

Place and promote the products across consumer channels.

International license partners

Use the brands in selected foreign territories under license agreements.

Strategia

The company is focused on extending its existing brands into new markets and launching adjacent products, especially within nutraceuticals and ready-to-drink beverages. It also seeks growth through strategic acquisitions that fit its brand portfolio, using licensing and distribution expansion to broaden reach.

Expand distribution for FOCUSfactor RTDsLyhyt aikaväli

Beverage distribution can widen the brand's reach and add a new consumption occasion.

Develop and launch new productsKeskipitkä aikaväli

Product extensions help deepen shelf presence and reduce reliance on a single SKU set.

Expand into selected foreign territoriesKeskipitkä aikaväli

Licensing can scale brands internationally with lower direct operating complexity.

Pursue strategic acquisitionsKeskipitkä aikaväli

Acquisitions can add brands and broaden the consumer health portfolio.

Maantiede

Synergy CHC Corp. is headquartered in the United States and appears to generate most of its business through U.S.-based consumer channels. The company also has license revenue tied to selected foreign territories, indicating some international brand reach even where direct operating detail is limited.

Riskit

The business depends on consumer demand, brand execution, and distribution access, so weak sell-through or delayed shipments can quickly affect results. It also carries financing and leverage risk, with interest expense and debt repayments playing a meaningful role in the capital structure. As a consumer health company, it faces competition, promotional pressure, product mix shifts, and the usual regulatory and claims-related scrutiny around supplements and wellness products.

Järjestetty vakavuuden mukaan
Customer concentration / non-repeat sell-inKorkea

Management disclosed that a new product sell-in to one customer in 2024 did not repeat in 2025, showing revenue sensitivity to individual orders.

Kohdistuu: Nutraceuticals revenue

Leverage and refinancing riskKorkea

The company relies on notes payable and related financing, making interest burden and repayment timing important.

Kohdistuu: Capital structure

Distribution and shipment timingKeskitaso

Packaging upgrades and shipment delays can move revenue across quarters and distort comparability.

Kohdistuu: FOCUSfactor and RTD launches

Regulatory and claims riskKeskitaso

Supplements and wellness products can face scrutiny over marketing claims, labeling, and product compliance.

Kohdistuu: FOCUSfactor and Flat Tummy

Promotional and channel competitionKeskitaso

Consumer health brands compete on shelf space, promotion, and brand awareness, which can affect sell-through.

Kohdistuu: Retail and distribution channels

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition

The company recognizes revenue from product sales and license agreements, so contract terms and delivery timing affect reported results.

Vaikutus: Can shift revenue between quarters and affect gross profit

Accounts receivable allowances

Management identifies receivable allowances as a critical estimate, reflecting collection uncertainty in consumer channels.

Vaikutus: Can affect net revenue and operating results

Non-GAAP EBITDA

EBITDA is used to evaluate performance but excludes interest, taxes, depreciation, and amortization.

Vaikutus: May differ materially from GAAP earnings and cash generation

License revenue timing

License agreements for selected foreign territories can create lumpier revenue recognition than product sales.

Vaikutus: Can increase period-to-period volatility

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026